166 related articles for article (PubMed ID: 26714964)
21. Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study.
Douillard JY; Siena S; Cassidy J; Tabernero J; Burkes R; Barugel M; Humblet Y; Bodoky G; Cunningham D; Jassem J; Rivera F; Kocákova I; Ruff P; Błasińska-Morawiec M; Šmakal M; Canon JL; Rother M; Oliner KS; Wolf M; Gansert J
J Clin Oncol; 2010 Nov; 28(31):4697-705. PubMed ID: 20921465
[TBL] [Abstract][Full Text] [Related]
22. Phase I/II trial of capecitabine, oxaliplatin, and irinotecan in combination with bevacizumab in first line treatment of metastatic colorectal cancer.
Bazarbashi S; Aljubran A; Alzahrani A; Mohieldin A; Soudy H; Shoukri M
Cancer Med; 2015 Oct; 4(10):1505-13. PubMed ID: 26207614
[TBL] [Abstract][Full Text] [Related]
23. Metastasectomy and BRAF mutation; an analysis of survival outcome in metastatic colorectal cancer.
Prasanna T; Wong R; Price T; Shapiro J; Tie J; Wong HL; Nott L; Roder D; Lee M; Kosmider S; Jalali A; Burge M; Padbury R; Maddern G; Carruthers S; Moore J; Sorich M; Karapetis CS; Gibbs P; Yip D
Curr Probl Cancer; 2021 Feb; 45(1):100637. PubMed ID: 32826083
[TBL] [Abstract][Full Text] [Related]
24. Maintenance strategies after first-line oxaliplatin plus fluoropyrimidine plus bevacizumab for patients with metastatic colorectal cancer (AIO 0207): a randomised, non-inferiority, open-label, phase 3 trial.
Hegewisch-Becker S; Graeven U; Lerchenmüller CA; Killing B; Depenbusch R; Steffens CC; Al-Batran SE; Lange T; Dietrich G; Stoehlmacher J; Tannapfel A; Reinacher-Schick A; Quidde J; Trarbach T; Hinke A; Schmoll HJ; Arnold D
Lancet Oncol; 2015 Oct; 16(13):1355-69. PubMed ID: 26361971
[TBL] [Abstract][Full Text] [Related]
25. Efficacy of triplet combination chemotherapy with oxaliplatin, irinotecan and capecitabine (OCX) in metastatic colorectal cancer in relation to RAS/RAF mutation status: results of a retrospective analysis.
Brunner S; von Moos R; Mey U; Camenisch Gross U; Freyholdt T; Cathomas R
Oncol Res Treat; 2014; 37(11):646-52. PubMed ID: 25427581
[TBL] [Abstract][Full Text] [Related]
26. Cetuximab plus FOLFOX-4 in untreated patients with advanced colorectal cancer: a Gruppo Oncologico dell'Italia Meridionale Multicenter phase II study.
Colucci G; Giuliani F; Garufi C; Mattioli R; Manzione L; Russo A; Lopez M; Parrella P; Tommasi S; Copetti M; Daniele B; Pisconti S; Tuveri G; Silvestris N; Maiello E
Oncology; 2010; 79(5-6):415-22. PubMed ID: 21474966
[TBL] [Abstract][Full Text] [Related]
27. A phase I/II study of biweekly capecitabine and irinotecan plus bevacizumab as second-line chemotherapy in patients with metastatic colorectal cancer.
Suenaga M; Mizunuma N; Matsusaka S; Shinozaki E; Ozaka M; Ogura M; Chin K; Yamaguchi T
Drug Des Devel Ther; 2015; 9():1653-62. PubMed ID: 25834402
[TBL] [Abstract][Full Text] [Related]
28. BRAF and RAS mutations as prognostic factors in metastatic colorectal cancer patients undergoing liver resection.
Schirripa M; Bergamo F; Cremolini C; Casagrande M; Lonardi S; Aprile G; Yang D; Marmorino F; Pasquini G; Sensi E; Lupi C; De Maglio G; Borrelli N; Pizzolitto S; Fasola G; Bertorelle R; Rugge M; Fontanini G; Zagonel V; Loupakis F; Falcone A
Br J Cancer; 2015 Jun; 112(12):1921-8. PubMed ID: 25942399
[TBL] [Abstract][Full Text] [Related]
29. BRAF-Mutated Colorectal Cancer Exhibits Distinct Clinicopathological Features from Wild-Type BRAF-Expressing Cancer Independent of the Microsatellite Instability Status.
Jang MH; Kim S; Hwang DY; Kim WY; Lim SD; Kim WS; Hwang TS; Han HS
J Korean Med Sci; 2017 Jan; 32(1):38-46. PubMed ID: 27914130
[TBL] [Abstract][Full Text] [Related]
30. Multicenter Phase II study of FOLFOX or biweekly XELOX and Erbitux (cetuximab) as first-line therapy in patients with wild-type KRAS/BRAF metastatic colorectal cancer: The FLEET study.
Soda H; Maeda H; Hasegawa J; Takahashi T; Hazama S; Fukunaga M; Kono E; Kotaka M; Sakamoto J; Nagata N; Oba K; Mishima H
BMC Cancer; 2015 Oct; 15():695. PubMed ID: 26467662
[TBL] [Abstract][Full Text] [Related]
31. Poor prognosis of KRAS or BRAF mutant colorectal liver metastasis without microsatellite instability.
Umeda Y; Nagasaka T; Mori Y; Sadamori H; Sun DS; Shinoura S; Yoshida R; Satoh D; Nobuoka D; Utsumi M; Yoshida K; Yagi T; Fujiwara T
J Hepatobiliary Pancreat Sci; 2013 Feb; 20(2):223-33. PubMed ID: 23010994
[TBL] [Abstract][Full Text] [Related]
32. High BRAF Mutation Frequency and Marked Survival Differences in Subgroups According to KRAS/BRAF Mutation Status and Tumor Tissue Availability in a Prospective Population-Based Metastatic Colorectal Cancer Cohort.
Sorbye H; Dragomir A; Sundström M; Pfeiffer P; Thunberg U; Bergfors M; Aasebø K; Eide GE; Ponten F; Qvortrup C; Glimelius B
PLoS One; 2015; 10(6):e0131046. PubMed ID: 26121270
[TBL] [Abstract][Full Text] [Related]
33. Phase III trial of cetuximab with continuous or intermittent fluorouracil, leucovorin, and oxaliplatin (Nordic FLOX) versus FLOX alone in first-line treatment of metastatic colorectal cancer: the NORDIC-VII study.
Tveit KM; Guren T; Glimelius B; Pfeiffer P; Sorbye H; Pyrhonen S; Sigurdsson F; Kure E; Ikdahl T; Skovlund E; Fokstuen T; Hansen F; Hofsli E; Birkemeyer E; Johnsson A; Starkhammar H; Yilmaz MK; Keldsen N; Erdal AB; Dajani O; Dahl O; Christoffersen T
J Clin Oncol; 2012 May; 30(15):1755-62. PubMed ID: 22473155
[TBL] [Abstract][Full Text] [Related]
34. Real-World Outcomes of Patients With BRAF-Mutated Metastatic Colorectal Cancer Treated in the United States.
Trunk A; Braithwaite M; Nevala-Plagemann C; Pappas L; Haaland B; Garrido-Laguna I
J Natl Compr Canc Netw; 2022 Feb; 20(2):144-150. PubMed ID: 35130499
[TBL] [Abstract][Full Text] [Related]
35. Prognostic Value of BRAF, PI3K, PTEN, EGFR Copy Number, Amphiregulin and Epiregulin Status in Patients with KRAS Codon 12 Wild-Type Metastatic Colorectal Cancer Receiving First-Line Chemotherapy with Anti-EGFR Therapy.
Llovet P; Sastre J; Ortega JS; Bando I; Ferrer M; García-Alfonso P; Donnay O; Carrato A; Jiménez A; Aranda E; León A; Grávalos C; Cámara JC; Feliú J; Sanchíz B; Caldés T; Díaz-Rubio E
Mol Diagn Ther; 2015 Dec; 19(6):397-408. PubMed ID: 26341080
[TBL] [Abstract][Full Text] [Related]
36. KRAS and BRAF mutational status in primary colorectal tumors and related metastatic sites: biological and clinical implications.
Italiano A; Hostein I; Soubeyran I; Fabas T; Benchimol D; Evrard S; Gugenheim J; Becouarn Y; Brunet R; Fonck M; François E; Saint-Paul MC; Pedeutour F
Ann Surg Oncol; 2010 May; 17(5):1429-34. PubMed ID: 20049644
[TBL] [Abstract][Full Text] [Related]
37. Exploring clinical and gene expression markers of benefit from FOLFOXIRI/bevacizumab in patients with BRAF-mutated metastatic colorectal cancer: Subgroup analyses of the TRIBE2 study.
Moretto R; Giordano M; Poma AM; Passardi A; Boccaccino A; Pietrantonio F; Tomasello G; Aprile G; Lonardi S; Conca V; Granetto C; Frassoldati A; Clavarezza M; Bertolini AS; Germani MM; Ugolini C; Fontanini G; Masi G; Falcone A; Cremolini C
Eur J Cancer; 2021 Aug; 153():16-26. PubMed ID: 34126333
[TBL] [Abstract][Full Text] [Related]
38. Biologic therapies in the metastatic colorectal cancer treatment continuum--applying current evidence to clinical practice.
Peeters M; Price T
Cancer Treat Rev; 2012 Aug; 38(5):397-406. PubMed ID: 21899955
[TBL] [Abstract][Full Text] [Related]
39. Phase II trial of cetuximab plus irinotecan for oxaliplatin- and irinotecan-based chemotherapy-refractory patients with advanced and/or metastatic colorectal cancer: evaluation of efficacy and safety based on KRAS mutation status (T-CORE0801).
Soeda H; Shimodaira H; Gamoh M; Ando H; Isobe H; Suto T; Takahashi S; Kakudo Y; Amagai K; Mori T; Watanabe M; Yamaguchi T; Kato S; Ishioka C
Oncology; 2014; 87(1):7-20. PubMed ID: 24968756
[TBL] [Abstract][Full Text] [Related]
40. Survival improvements associated with access to biological agents: Results from the South Australian (SA) metastatic colorectal cancer (mCRC) registry.
Tomita Y; Karapetis CS; Ullah S; Townsend AR; Roder D; Beeke C; Roy AC; Padbury R; Price TJ
Acta Oncol; 2016; 55(4):480-5. PubMed ID: 26878155
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
